Shilpa Medicare receives EIR from USFDA for Telangana facility

17 Mar 2018 Evaluate

Shilpa Medicare has received Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between November 11 and November 30, 2017. USFDA has determined that the inspection classification of this facility is VAI and accordingly EIR issued.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

290.75 -2.15 (-0.73%)
19-Jan-2026 10:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1661.85
Dr. Reddys Lab 1170.20
Cipla 1376.35
Zydus Lifesciences 864.75
Lupin 2167.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×